Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 521540 of 20,252 grants

Active NON-SBIR/STTR RPGS
Administrative Core
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2024 – 2029

CORE A SUMMARY/DESCRIPTION Core A is critical to the operation of this program project, and has three major aims. In Aim 1, core A will initiate and organize regular communication...

Active NON-SBIR/STTR RPGS
Replication Stress Sensing and Signaling Defects in SCLC
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2024 – 2029

PROJECT SUMMARY The underlying mechanisms that account for initial sensitivity to of SCLC to chemotherapy followed by profound therapeutic resistance are just beginning to be eluci...

Active NON-SBIR/STTR RPGS
Roles of TIMELESS in oncogene-induced senescence and oncogenic transformation
NATIONAL CANCER INSTITUTE State University New York Stony Brook United States 2024 – 2029

PROJECT SUMMARY Oncogenic stimuli in early cancerous lesions, such as driven by RAS mutations, triggers oncogene-induced senescence (OIS), which acts as a barrier to prevent malign...

$3.59M
USD
Active NON-SBIR/STTR RPGS
From Perceptions to Behaviors: A Comprehensive Approach to Examine the Impact of Public Health Communication Messaging about the Continuum of Risk for Tobacco Products
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2024 – 2028

PROJECT SUMMARY Effective communication strategies are urgently needed to convey the relative risks of tobacco products accurately among adults who currently use combustible tobacc...

$24.9M
USD
Active TRAINING, INDIVIDUAL
Development and application of whole-body patient-specific computational mesh phantoms for organ dosimetry and second primary cancer risk quantification following external beam radiotherapy
NATIONAL CANCER INSTITUTE University of Florida United States 2024 – 2027

PROJECT SUMMARY Approximately half of all cancer patients in the United States are treated with external beam radiotherapy (RT), with approximately 40% of all curative treatment be...

$439K
USD
Active TRAINING, INDIVIDUAL
Improving engineered TCR-T cell therapy for solid tumors by targeting Tcf1+ stem-like reservoirs in tumor-draining lymph nodes
NATIONAL CANCER INSTITUTE Fred Hutchinson Cancer Center United States 2024 – 2026

PROJECT SUMMARY Adoptive transfer of engineered T cells targeting tumor antigens is ineffective against most solid tumors, due in-part to poor persistence and the rapid onset of dy...

$441.5K
USD
Active TRAINING, INDIVIDUAL
Enzyme-Mediated Depletion of Extracellular Adenosine and 5'methylthioadenosine as a Novel Anti-Cancer Therapeutic
NATIONAL CANCER INSTITUTE University of Texas At Austin United States 2024 – 2027

PROJECT SUMMARY In recent years, adenosine has been identified as an important therapeutic target due to its observed immunosuppressive effects in the tumor microenvironment. By ag...

$465.9K
USD
Active TRAINING, INDIVIDUAL
Defining the role of NUDT5 in ovarian cancer
NATIONAL CANCER INSTITUTE University of California Los Angeles United States 2024 – 2027

Ovarian cancer patients are burdened with a lack of effective therapeutic options resulting in a low survival rate due to chemotherapy resistance, recurrence, and metastasis. The o...

$456.4K
USD
Active NON-SBIR/STTR RPGS
Mechanisms of Replication Stress Tolerance in SCLC
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2024 – 2029

PROJECT 2 SUMMARY Exacerbating replication stress is a powerful means to kill cancer cells through mitotic catastrophe due to intolerable levels of DNA replication-associated lesio...

Active NON-SBIR/STTR RPGS
Repair Mechanisms of Replication fork Lesions in SCLC
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2024 – 2029

PROJECT SUMMARY This project will investigate the specific mechanisms of DNA lesions that are generated in SCLC during treatment and lead to response or resistance to therapy. This...

Active NON-SBIR/STTR RPGS
Impact of recurrent genetic alterations on SCLC subtypes and therapeutic response
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2024 – 2029

Project Summary Small cell lung cancer (SCLC) is a highly aggressive malignancy with high heterogeneity and few available treatment options. SCLC cells are of highly plastic enabli...

Active NON-SBIR/STTR RPGS
SCLC Model Generation and Therapeutic Analysis
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2024 – 2029

Project Summary The laboratory mouse plays a central role in the preclinical development of new therapeutic strategies and through the application of transgenic technology has prov...

Active NON-SBIR/STTR RPGS
Advanced Imaging and Computational Approaches
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2024 – 2029

The Advanced Microscopy and Computational Approaches Core (Core C) will provide advanced imaging and computational approaches to support this Program Project in elucidating the mol...

Active OTHER RESEARCH-RELATED
An Acceptance and Commitment Therapy-Based Psychosocial Intervention to Alleviate Distress and Promote Adaptive Coping Skills in Patients with Malignant Primary Central Nervous System Tumors
NATIONAL CANCER INSTITUTE Massachusetts General Hospital United States 2024 – 2029

Project Summary/Abstract Malignant primary central nervous system (CNS) tumors are incurable tumors characterized by high symptom burden and poor survival. In addition to the sympt...

$2.93M
USD
Active OTHER RESEARCH-RELATED
Dissecting the cooperation of FOXR2 and ETS transcription factors in FOXR2-expressing diffuse midline gliomas
NATIONAL CANCER INSTITUTE Children'S Hospital of Los Angeles United States 2024 – 2029

PROJECT SUMMARY Diffuse midline gliomas (DMGs) are devastating childhood brain tumors for which there are no effective therapies. While histone mutations are thought to be a critic...

$2.63M
USD
Completed SBIR-STTR RPGS
Stroma-penetrating nanomedicine to improve treatment for pancreatic cancer
NATIONAL CANCER INSTITUTE Duo Oncology Inc United States 2024 – 2025

PROJECT SUMMARY Annually, pancreatic cancer (PC) has a global incidence of more than 495,000 cases and a mortality rate of almost 460,000 cases. Most of these patients (~80%) recei...

$4M
USD
Active NON-SBIR/STTR RPGS
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer
NATIONAL CANCER INSTITUTE Washington University United States 2024 – 2029

Abstract Prostate cancer (PC) is one of the leading cause of cancer deaths among American men. Advanced PC patients often receive androgen deprivation therapy, but, the recalcitran...

$6.52M
USD
Active NON-SBIR/STTR RPGS
Rewired Metabolism and Immunosuppression in MYCN-driven Neuroblastoma
NATIONAL CANCER INSTITUTE Baylor College of Medicine United States 2024 – 2029

PROJECT SUMMARY Amplification of the oncogene MYCN drives high-risk progressive disease, resistance to therapy, and a poor overall survival rate below 45% for high-risk neuroblasto...

$4.32M
USD
Active NON-SBIR/STTR RPGS
Cell Competition in Development and Homeostasis
NATIONAL CANCER INSTITUTE University of California-Irvine United States 2024 – 2029

A process of cell competition can remove cells that differ genetically from neighboring cells in the same tissues. Cell competition helps to eliminate sporadic aneuploid cells that...

$4.09M
USD
Active NON-SBIR/STTR RPGS
Targeting mitochondrial calcium to eradicate leukemia-initiating cells
NATIONAL CANCER INSTITUTE University of Colorado Denver United States 2024 – 2029

SUMMARY The goal of this project is to develop strategies for the eradication of leukemia-initiating cells (LICs) in AML patients who have received initial therapy with venetoclax...

$4.37M
USD